journal
MENU ▼
Read by QxMD icon Read
search

Pharmacogenomics

journal
https://www.readbyqxmd.com/read/28290774/multimorbidity-polypharmacy-and-pharmacogenomics-in-old-age
#1
Jürgen Brockmöller, Julia C Stingl
No abstract text is available yet for this article.
March 14, 2017: Pharmacogenomics
https://www.readbyqxmd.com/read/28290771/institutional-profile-pharmacogenomic-research-in-r-stephanie-huang-laboratory
#2
Paul Geeleher, Aritro Nath, Rong Stephanie Huang
The Huang Lab was established in 2009 at the University of Chicago and has since been active in conducting pharmacogenomic research. Our laboratory's main research focus is translational pharmacogenomics with a particular interest in the pharmacogenomics of anticancer agents. By systematically evaluating the human genome and its relationships to drug response and toxicity, our goal is to develop clinically useful models that predict risk for adverse drug reactions and nonresponse prior to administration of chemotherapy...
March 14, 2017: Pharmacogenomics
https://www.readbyqxmd.com/read/28290770/in-vivo-characterization-of-cyp2d6-12-29-and-84-using-dextromethorphan-as-a-probe-drug-a-case-report
#3
Andrea Gaedigk, Greyson P Twist, Emily G Farrow, Jennifer A Lowry, Sarah E Soden, Neil A Miller
CYP2D6*84 was first described in a Black South African subject, however, its function remains unknown. Astrolabe, a probabilistic scoring tool developed in our laboratory to call genotypes from whole genome sequence, identified CYP2D6*84 in a trio. The father presented with intermediate metabolism when challenged with the CYP2D6 probe drug dextromethorphan (DM/dextrorphan [DX] = 0.0839). Since his second allele, CYP2D6*12, is nonfunctional, the observed activity is derived by CYP2D6*84. This finding suggests that the allele's hallmark P267H causes decreased activity toward DM and that this allele should receive a value of 0...
March 14, 2017: Pharmacogenomics
https://www.readbyqxmd.com/read/28290769/sequencing-brain-metastases-and-opportunities-for-targeted-therapies
#4
Ugonma N Chukwueke, Priscilla K Brastianos
CNS metastases have long been recognized as a common and late complication of systemic malignancies. They represent the most common tumor of the brain. As outcomes and overall survival improve with better tolerated and more durable responses from therapies for systemic cancers, the incidence and prevalence of brain metastases is likely to increase. Among the most common systemic cancers leading to brain metastases include lung, melanoma, breast (triple-negative histology) and renal cell cancers. To date, there has been infrequent involvement of gastrointestinal and gynecologic malignancies; however, this may also change, reflecting improvement in overall survival and therapeutic regimens...
March 14, 2017: Pharmacogenomics
https://www.readbyqxmd.com/read/28290747/clinicians-perceptions-of-pharmacogenomics-use-in-psychiatry
#5
Christopher Yi Wen Chan
AIM: This study aims to assess the attitudes and opinions of clinicians practicing in psychiatry toward pharmacogenomic testing, and in so doing elicits possible barriers and risks to employ this technology in patient care. MATERIALS & METHODS: Doctors and pharmacists presently practicing in psychiatry were invited to participate in an anonymous web-based survey. Besides information on participant characteristics and experience in psychiatry, specific themes on pharmacogenomics including self-assessed competency, perceived usefulness in clinical situations, perceived risks and preferred mode of education were evaluated...
March 14, 2017: Pharmacogenomics
https://www.readbyqxmd.com/read/28244813/pharmacogenomics-of-autism-spectrum-disorder
#6
Jacob T Brown, Seenae Eum, Edwin H Cook, Jeffrey R Bishop
Autism spectrum disorder (ASD) is characterized by persistent deficits in social communication and interactions as well as restricted, repetitive behaviors and interests. Pharmacologic interventions are often needed to manage irritability, aggressive behaviors and hyperactivity. Pharmacogenomic studies have investigated genetic associations with treatment response and side effects in an attempt to better understand drug mechanisms in hopes of optimizing the balance of symptom improvement versus side effects...
March 2017: Pharmacogenomics
https://www.readbyqxmd.com/read/28244812/primary-care-providers-use-of-pharmacist-support-for-delivery-of-pharmacogenetic-testing
#7
Susanne B Haga, Rachel Mills, Jivan Moaddeb, Nancy Allen LaPointe, Alex Cho, Geoffrey S Ginsburg
AIM: To investigate provider utilization of pharmacist support in the delivery of pharmacogenetic testing in a primary care setting. METHODS: Two primary care clinics within Duke University Health System participated in the study between December 2012 and July 2013. One clinic was provided with an in-house pharmacist and the second clinic had an on-call pharmacist. RESULTS: Providers in the in-house pharmacist arm consulted with the pharmacist for 13 of 15 cases, or about one of every four patients tested compared with one of every 7...
March 2017: Pharmacogenomics
https://www.readbyqxmd.com/read/28244811/systematic-screening-for-cyp3a4-genetic-polymorphisms-in-a-han-chinese-population
#8
Guo-Xin Hu, Da-Peng Dai, Hao Wang, Xiang-Xin Huang, Xiao-Yang Zhou, Jie Cai, Hao Chen, Jian-Ping Cai
AIM: To systematically investigate the genetic polymorphisms of the CYP3A4 gene in a Han Chinese population. MATERIALS & METHODS: The promoter and exons of CYP3A4 gene in 1114 unrelated, healthy Han Chinese subjects were amplified and genotyped by direct sequencing. RESULTS: In total, five previously reported alleles (*1G, *4, *5, *18B and *23) were detected, of which one allele (*23) was reported for the first time in Han Chinese population...
March 2017: Pharmacogenomics
https://www.readbyqxmd.com/read/28244810/corrigendum
#9
(no author information available yet)
No abstract text is available yet for this article.
March 2017: Pharmacogenomics
https://www.readbyqxmd.com/read/28244809/is-there-a-role-for-pharmacogenetics-in-the-treatment-of-sickle-cell-disease
#10
Ambroise Wonkam
No abstract text is available yet for this article.
March 2017: Pharmacogenomics
https://www.readbyqxmd.com/read/28244808/cyp2d6-pharmacogenetic-and-oxycodone-pharmacokinetic-association-study-in-pediatric-surgical-patients
#11
Rajiv Balyan, Marc Mecoli, Raja Venkatasubramanian, Vidya Chidambaran, Nichole Kamos, Smokey Clay, David L Moore, Jagroop Mavi, Chris D Glover, Peter Szmuk, Alexander Vinks, Senthilkumar Sadhasivam
AIM: Oxycodone is partly metabolized to the active metabolite oxymorphone by hepatic CYP2D6 in the liver. Significant genetic variability in CYP2D6 activity affects oxymorphone formation. This study aimed to associate CYP2D6 genotype and oxycodone's metabolism. METHODS: 30 children were administered oral oxycodone postoperatively. Plasma levels of oxycodone and oxymorphone, and CYP2D6 genotype were analyzed. CYP2D6 genotype and oxycodone metabolism phenotype were determined based on CYP2D6 total activity score (TAS) and metabolism phenotype: poor metabolizer (PM), intermediate metabolizer (IM), extensive metabolizer (EM) or ultrarapid metabolizer (UM)...
March 2017: Pharmacogenomics
https://www.readbyqxmd.com/read/28244807/nfatc1-genotypes-affect-acute-rejection-and-long-term-graft-function-in-cyclosporine-treated-renal-transplant-recipients
#12
Qinxia Xu, Xiaoyan Qiu, Zheng Jiao, Ming Zhang, Jianping Chen, Mingkang Zhong
AIM: To investigate the effects of SNPs in the cyclophilin A/calcineurin/nuclear factor of activated T-cells (NFATs) pathway genes (PPIA, PPP3CB, PPP3R1, NFATC1 and NFATC2) on cyclosporine (CsA) efficacy in renal transplant recipients. MATERIALS & METHODS: Seventy-six tag SNPs were detected in 155 CsA-treated renal recipients with at least a 5-year follow-up. The associations of SNPs with acute rejection, nephrotoxicity, pneumonia and estimated glomerular filtration rate post transplant were explored...
March 2017: Pharmacogenomics
https://www.readbyqxmd.com/read/28244806/the-need-for-precision-medicine-clinical-trials-in-childhood-asthma-rationale-and-design-of-the-puffin-trial
#13
Susanne Jh Vijverberg, Mariëlle W Pijnenburg, Anke M Hövels, Gerard H Koppelman, Anke-Hilse Maitland-van der Zee
A 'one-size fits all'-approach does not fit all pediatric asthma patients. Current evidence suggests that in children with persistent asthma, ADRB2 genotype-guided treatment can improve treatment outcomes, yet this evidence is mainly derived from observational and genotype-stratified studies. Implementation of precision medicine-guided asthma treatment in clinical practice will only occur if randomized clinical trials can show that this approach will improve patient outcomes and is cost effective. In this paper, we will discuss why precision medicine trials are currently needed to improve childhood asthma management and present the rationale and design of the PUFFIN trial, that has been set up to address this need...
March 2017: Pharmacogenomics
https://www.readbyqxmd.com/read/28244805/no-impact-of-eight-ntrk2-genetic-polymorphisms-on-6-month-antidepressant-efficacy-in-depressed-patients
#14
Eric Deflesselle, Céline Verstuyft, Anne-Cécile Petit, Patrick Hardy, Denis J David, Bruno Falissard, Bruno Fève, Laurent Rigal, Laurent Becquemont, Emmanuelle Corruble, Romain Colle
AIM: NTRK2 is the main receptor of the brain derived neurotrophic factor, which is involved in antidepressant efficacy. We assessed the impact of eight NTRK2 SNPs pertaining to response and remission after antidepressant treatment in depressed patients. PATIENTS & METHODS: In a naturalistic study, 569 patients with a major depressive episode requiring a new antidepressant treatment were genotyped for eight NTRK2 SNPs (rs1187352, rs1439050, rs1778933 rs2289656, rs2289657, rs2289658, rs3824519, rs56142442) and prospectively assessed for response and remission after 6 months of treatment...
March 2017: Pharmacogenomics
https://www.readbyqxmd.com/read/28244804/assessing-feasibility-of-delivering-pharmacogenetic-testing-in-a-community-pharmacy-setting
#15
Susanne B Haga, Jivan Moaddeb, Rachel Mills, Deepak Voora
AIM: To describe the rationale and design of a study evaluating the delivery of pharmacogenetic (PGx) testing in community pharmacies. Study rationale: Pharmacists have expressed interest in offering PGx testing; however, their lack of knowledge and experience, patients' acceptance and feasibility are unknown in this setting. STUDY DESIGN: Through a cluster randomized trial, we will assess pharmacist and patient experiences with delivery of PGx testing as a standalone service or integrated into medication therapy management services...
March 2017: Pharmacogenomics
https://www.readbyqxmd.com/read/28128025/corrigendum
#16
(no author information available yet)
No abstract text is available yet for this article.
February 2017: Pharmacogenomics
https://www.readbyqxmd.com/read/28112993/the-role-of-pharmacogenetics-in-the-new-esmo-colorectal-cancer-guidelines
#17
Marta Schirripa, Letizia Procaccio, Sara Lonardi, Fotios Loupakis
No abstract text is available yet for this article.
February 2017: Pharmacogenomics
https://www.readbyqxmd.com/read/28112992/a-nationwide-survey-of-pharmacists-perception-of-pharmacogenetics-in-the-context-of-a-clinical-decision-support-system-containing-pharmacogenetics-dosing-recommendations
#18
Paul Cd Bank, Jesse J Swen, Henk-Jan Guchelaar
AIM: To benchmark Dutch pharmacists knowledge, experience and attitudes toward pharmacogenetics (PGx) with a specific focus on the effects of awareness of the Dutch Pharmacogenetics Working Group guidelines. METHODS: A web-based survey containing 41 questions was sent to all certified Dutch pharmacists. RESULTS: A total of 667 pharmacists completed the survey (18.8%). Virtually all responders believed in the concept of PGx (99.7%). However, only 14...
February 2017: Pharmacogenomics
https://www.readbyqxmd.com/read/28112990/alk-gene-alterations-in-cancer-biological-aspects-and-therapeutic-implications
#19
Raffaele Palmirotta, Davide Quaresmini, Domenica Lovero, Franco Silvestris
ALK was first reported in 1994 as a translocation in anaplastic large cell lymphoma and then described with different abnormalities in a number of tumors. Recently, a shortly accumulated biomedical research clarified the numerous biological processes underlying its ability to support cancer development, growth and progression. Advent of precision medicine has finally provided unexpected advances, leading to the development of ALK-targeting inhibitors with superior efficacy as compared with standard chemotherapy regimens, as well as the identification of resistance mechanisms and the creation of 'next-generation' treatments...
February 2017: Pharmacogenomics
https://www.readbyqxmd.com/read/28112586/genetic-variation-in-the-glucocorticoid-pathway-involved-in-interindividual-differences-in-the-glucocorticoid-treatment
#20
Qian-Qian Song, Wan-Ying Xie, Yong-Jun Tang, Jun Zhang, Jie Liu
Glucocorticoids (GCs) are widely used for treating asthma, rheumatoid arthritis, nephrotic syndrome, acute lymphoblastic leukemia and other autoimmune diseases. However, in a subgroup of patients, failure to respond to GCs is known as GC resistance or GC insensitivity. This represents an important barrier to effective treatment and a clinical problem requiring an urgent solution. Genetic variation in the GC pathway is a significant factor in interindividual differences in GC treatment. This article reviews the pharmacogenetics of GCs in diverse diseases based on the GC pathway...
February 2017: Pharmacogenomics
journal
journal
34814
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"